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support sister chromatid cohesion
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Warsaw Breakage Syndrome (WABS) is a rare disorder related to cohesinopathies and
Fanconi anemia, caused by bi-allelic mutations in DDX11. Here, we report multiple compound
heterozygous WABS cases, each displaying destabilized DDX11 protein and residual DDX11
function at the cellular level. Patient-derived cell lines exhibit sensitivity to topoisomerase and
PARP inhibitors, defective sister chromatid cohesion and reduced DNA replication fork speed.
Deleting DDX11 in RPE1-TERT cells inhibits proliferation and survival in a TP53-dependent
manner and causes chromosome breaks and cohesion defects, independent of the expressed
pseudogene DDX12p. Importantly, G-quadruplex (G4) stabilizing compounds induce chro-
mosome breaks and cohesion defects which are strongly aggravated by inactivation of DDX11
but not FANCJ. The DNA helicase domain of DDX11 is essential for sister chromatid cohesion
and resistance to G4 stabilizers. We propose that DDX11 is a DNA helicase protecting against
G4 induced double-stranded breaks and concomitant loss of cohesion, possibly at DNA
replication forks.
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Warsaw Breakage Syndrome (WABS) was discovered in2010 in a patient displaying remarkable clinical over-lap with Fanconi anemia (FA), a DNA damage syn-
drome characterized by impaired DNA crosslink repair, including
growth retardation, microcephaly, and abnormal skin pigmenta-
tion, although bone marrow failure was not observed 1. Both FA
and WABS patient-derived cells exhibit mitomycin C (MMC)-
induced chromosomal breaks but only WABS cells typically show
spontaneous loss of sister chromatid cohesion at metaphase2,3.
Such cohesion loss is significantly exacerbated by treatment with
MMC or the topoisomerase I inhibitor camptothecin (CPT). Bi-
allelic mutations in DDX11 were identified as the WABS-
underlying genetic defect. Previously, sixteen WABS individuals
from twelve different families had been reported carrying bi-
allelic DDX11 mutations1,4–9.
DDX11 (also known as ChlR1) is one of the two human
orthologues of yeast Chl1, a DNA helicase that was identified in a
screen for mutants affecting chromosome segregation10,11. The
other orthologue is DDX12p (also known as ChlR2)12,13, a pre-
sumed pseudogene linked to a late-evolutionary duplication of a
DDX11-containing region on chromosome 12. Parish and col-
leagues showed that DDX11 protein localizes to the nucleus and
supports sister chromatid cohesion14 which fits with later findings
in WABS cells. DDX11 loss in mice is embryonically lethal15,16,
apparently contradicting the observed viability of yeast Chl1
mutants10,11,17 and the relatively moderate symptoms of human
WABS patients.
Sequence similarities classify DDX11 in a subgroup of DEAD/
H box, ATP-dependent, super-family 2 (SF2) RNA or DNA
helicases that contain an iron–sulfur cluster (Fe–S) between the
Walker A and B boxes18. Other members include FANCJ, RTEL1,
and XPD/ERCC2, all linked to genetic disorders characterized by
defects in DNA repair mechanisms. Several in vitro studies19–22
revealed that DDX11 unwinds duplex DNA in an ATP-
dependent manner with 5′–3′ directionality, preferring DNA
substrates with a 5′ single-stranded region. As recently
reviewed23, substrates include forked duplexes, 5′ flap structures
(relevant in the processing of Okazaki fragments), three-stranded
D-loops (early HR repair intermediates) and anti-parallel
G-quadruplexes (G4s) that may form in stretches of G-rich
DNA. Interestingly, mutating both chl-1 and dog-1 (the C. elegans
orthologs of DDX11 and FANCJ) increased the number of
deletions in poly-guanine tracts as compared to single dog-1
mutants, suggesting a potential role for DDX11 in resolving G4 or
related poly-guanine duplex structures in vivo24.
Yeast Chl1 mutant strains show increased sensitivity to DNA
damaging agents including MMS and UV17,25. In addition,
Chl1 supports the establishment of sister chromatid
cohesion26,27, a process coupled to DNA replication28,29.
Unwinding of duplex DNA at the replication fork is performed by
the Cdc45-MCM (mini-chromosome-maintenance)-GINS (go-
ichi-ni-san) (CMG) complex. Specialized DNA polymerases
synthesize DNA in conjunction with a homo-trimeric pro-
liferating cell nuclear antigen (PCNA) sliding clamp that is loaded
onto DNA by the replication factor C (RFC) complex. Other
components of the DNA replication machinery include Tof1/
Timeless, Csm3/Tipin, Mrc1/Claspin, and Ctf4/AND-1, which all
play important roles in maintaining DNA replication fork stabi-
lity by coordinating DNA unwinding with synthesis and the
association with S phase checkpoint proteins (reviewed in ref. 30).
CHL1 interacts genetically with multiple components of the
alternative RFCCTF18 complex, including CTF18, CTF8, and DCC1,
which are implicated in cohesion establishment, too27,31–34. Phy-
sical interactions were also reported between Chl1 and PCNA35,
Ctf436, and the 5′-flap endonuclease Fen-137. Human DDX11
binds PCNA20, WDHD1, POL δ38, FEN1, promoting FEN1
activity, and RFCCHTF18 which stimulates DDX11 helicase
activity in vitro. Furthermore, a role for DDX11 was proposed in
stabilization of the replication fork through an interaction with
Timeless, a circadian rhythm regulatory gene. DDX11-Timeless
complexes support DNA binding and helicase activity of DDX11
in vitro and promote sister chromatid cohesion39–41. Whether
DDX11 helicase activity is critically involved in connecting DNA
replication and sister chromatid cohesion, and, if so, which DNA
substrates are targeted by DDX11 in vivo, remains a matter of
debate. Hypothetically, DDX11 could facilitate sister chromatid
entrapment into cohesin rings by resolving secondary DNA
structures formed at replication sites, for instance in the lagging
strand or in ssDNA formed during repair of stalled forks. Indeed,
abolishing the ATPase activity in yeast Chl142 and in avian
DDX1143 resulted in loss of sister chromatid cohesion. However,
dominant helicase-independent roles in cohesin loading have also
been proposed36,41.
Here, we identify seven new WABS patients from five different
families. WABS-derived cells display loss of sister chromatid
cohesion, increased sensitivity to CPT or PARP inhibitors and
reduced replication fork speed. The investigated WABS cells
retain residual DDX11 activity, originating from an unstable
protein. Nevertheless, several of the identified mutant alleles are
capable of rescuing sister chromatid cohesion when over-
expressed in WABS patient cells, showing they are hypomorphic
mutations with only partial loss of function. Inactivating DDX11
in diploid human epithelial cells causes TP53-dependent growth
restriction and increased RAD51 dependence. While we show
that DDX12p is expressed as mRNA, we observed no com-
plementary role for DDX12p. DDX11 deficient cells display very
high sensitivity to G4-stabilizing drugs, exceeding that of cells
deficient for other putative G4 helicases FANCJ, BLM, and WRN.
The DDX11 helicase domain is strictly required for sister chro-
matid cohesion. We propose therefore that DDX11 unwinds
G4 structures that may arise when replication forks travel
through G-rich regions, thus preventing breaks and promoting
efficient DNA entrapment by cohesin rings. This likely con-
tributes to genomic stability and cellular fitness.
Results
Clinical characterization of seven new WABS cases. The first
WABS patient was reported by our lab in 20101, which we
now call WABS01. Here, we investigated cell lines derived
from seven new WABS patients (WABS02–WABS08) with non-
consanguineous parents and of different origins. WABS02 (male)
is the second child of Dutch parents, initially diagnosed with
Nijmegen Breakage Syndrome (NBS), although no NBS1 muta-
tions were found44. He showed growth retardation, microcephaly,
deafness and abnormal skin pigmentation. WABS03 (male) is the
second child of Uruguayan parents. He received pediatric inten-
sive care for several months after birth due to respiratory pro-
blems, showed severe developmental delay, microcephaly,
sensorineural deafness, hyperactivity, and multiple broncho-
obstructive episodes. Also congenital hypothyroidism, low set
ears and retrognathia were observed. WABS04 (female) is the first
child of Dutch parents, initially diagnosed with FA with unknown
genetic cause45. She was born at the 7th month of pregnancy
weighing 750 g and had epileptic episodes at the age of three, and
childhood hyperactivity as described by the mother. At the age of
45, the following clinical features were recorded: growth and
mental retardation, deafness, microcephaly, skin pigmentation
(café-au-lait spots), facial dysmorphy, bulbous nose, clinodactyly
of the 5th fingers, insulin-dependent diabetes mellitus and fre-
quent respiratory and middle-ear infections. No typical indica-
tions of anemia or malignancies were observed. She died at the
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age of 64, no autopsy report is available. WABS04 had three
unaffected siblings and a brother with clinical features that may
have been overlapping. The brother was likely affected, too, but
he died of heart failure at the age of 50 before a WABS diagnosis
was confirmed45. WABS05 (male) is the fourth child of non-
consanguineous parents from Croatia. He showed prenatal
growth retardation; his birth weight, after 36 weeks, was 1660 g.
He suffered epileptic seizures at the age of seven and displayed
brachy-microcephaly, moderate to severe intellectual disability,
bronchial asthma, clinodactyly of the 5th fingers, flexion con-
tractures of thumbs and sandal gap of toes and he is deaf-mute.
Cytogenetic investigation showed a 47XXY karyotype and cohe-
sion defects. WABS06 (female) is the older sister of WABS05. Her
birth weight, after 37 weeks, was 2100 g. She shows brachy-
microcephaly, abnormal skin pigmentation (café-au-lait spots),
clinodactyly of the 5th fingers, sandal gap of toe and is deaf-mute.
At early age, her intellectual development was estimated to be
normal but later declined. WABS07 (male) is a fetus of Dutch
parents. The pregnancy was prematurely abrogated due to severe
growth restriction of the fetus and placental abnormalities.
Furthermore, the fetus showed mild dysmorphic characteristics,
lung hypoplasia, increased liver-brain ratio, unilateral kidney
dysplasia and skin abnormalities. WABS08 (male) is a younger
fetus of the same parents, also from a pregnancy prematurely
abrogated due to severe embryonic growth retardation. In addi-
tion, multiple miscarriages with unknown genotype were repor-
ted, possibly relevant in the light of placental abnormalities
observed in DDX11 knockout mice15. Table 1 summarizes the
clinical phenotype of all known WABS cases, including the seven
patients of this study. Notably, while growth retardation, micro-
cephaly, clinodactyly, and deafness appear to be distinctive
diagnostic features of WABS, significant anemia was not
observed, as opposed to the vast majority of FA subtypes. Some
clinical overlap with the DNA damage repair deficiency syn-
drome NBS is also noteworthy (see ref. 44) but we also found no
clear evidence for the severe immunodeficiency linked to NBS.
While conclusive assessment of increased cancer risk, typical for
NBS or FA, requires further follow up, WABS patients appear to
lack childhood malignancies or other signs of hereditary cancer
predisposition. Finally, not all of the manifestations are shared
Table 1 Clinical features of known WABS patients.
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between WABS patients, confirming that WABS is a hetero-
geneous disease sharing overlap with both DNA damage syn-
dromes and cohesinopathies46–48.
Molecular characterization of newly identified WABS cases. Bi-
allelic mutations in DDX11 were detected in these patients
using whole exome sequencing and/or RNA sequencing, which
we confirmed using Sanger sequencing of genomic DNA and
cDNA (Fig. 1a and Supplementary Fig. 1). These mutations
further extend the list of reported WABS variants (Table 2). For
patient WABS03, only one correctly segregating missense
mutation (c.419G>A; p.R140Q) could be identified next to the
indicated c.1403 duplication. However, it remains unclear
whether DDX11 R140Q is a penetrant pathogenic allele (see
below).
Accurate WABS diagnosis depends on DDX11 sequencing
which is sometimes hampered by the pseudogene DDX12p,
which shares 98% sequence similarity to DDX11, as well as by
multiple sub-telomeric DDX11L sequences highly similar to
the DDX11 C-terminus49. Since DDX12p is also transcribed into
mRNA, in several occasions cloning of PCR fragments and
subsequent sequencing was required to confirm that the
mutations are present in DDX11 (Supplementary Fig. 1a–e).
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Fig. 1 Identification of multiple new Warsaw Breakage Syndrome (WABS) cases. a Pedigrees of seven new WABS patients. X indicates absence of
paternal DNA; question mark indicates uncertain whether patient has WABS; diamond indicates unknown sex; triangle indicates fetus. Nomenclature is
based on DDX11 transcript variant NM_030653.4. b Western blots of patient-derived lymphoblasts (L) and fibroblasts (F). DDX11 protein levels were
restored by stable transfection of DDX11 cDNA. Examples of two independent protein analyses are shown. c Wild-type lymphoblasts HSC93, FANCM-
deficient lymphoblasts VU867-L80, three WABS-derived lymphoblasts and their complemented counterparts were continuously exposed to increasing
Camptothecin concentrations, in two or three independent experiments. After three population doublings of untreated cells, cells were counted and plotted
as percentage of untreated cells. dmetaphase spreads of cells treated as in (c) were assessed for chromosome breaks, n= 50 for each condition. Depicted
examples of counted aberrations include a chromatid gap, a dislocated broken piece and a chromatid interchange figure (‘triradial’).
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As reported previously for other WABS cases, we observed
reduced DDX11 protein levels (Fig. 1b) and increased CPT
sensitivity (Fig. 1c), which correlated with induction of
chromosomal breaks (Fig. 1d). We also observed the spontaneous
cohesion loss typical for WABS, which was aggravated by CPT
treatment and corrected by stably expressing DDX11 cDNA
(Fig. 2a). Furthermore, consolidating our earlier observation in
two WABS-derived lymphoblast cell lines50, all WABS cell lines
demonstrated high sensitivity to PARP inhibition (PARPi).
WABS cells were considerably more sensitive to PARPi than
Roberts Syndrome (RBS) and Cornelia de Lange Syndrome
(CdLS) cells but similarly sensitive as FA cells (Fig. 2b). In line,
WABS01 fibroblasts exhibited increased cohesion loss, G2/M
induction and cell death upon treatment with the PARPi
Talazoparib (Supplementary Fig. 2).
DDX11 has a role in averting DNA damage in unperturbed
cells as well, reflected by the elevated number of γH2AX foci in
WABS cells as compared to corrected cells (Fig. 2c). Since DDX11
interacts with DNA replication regulators, its primal activity may
reside at the replication fork. Reduced replication fork speed was
reported in HeLa cells when DDX11 knockdown was combined
with the nucleotide-depleting agent hydroxyurea40, potentially
reflecting the requirement for DDX11 to allow fork progression
through difficult-to-replicate regions of DNA. In agreement with
this observation, we recently reported slower fork progression
upon DDX11 depletion in RPE1 cells51. However, in unchal-
lenged and MMS treated chicken DT40 cells, DNA replication
appeared to be independent of DDX1152. Notably, avian cells
may possess increased DNA repair efficiencies which could
compensate for DDX11 loss and might explain the reduced
impact. To assess replication fork dynamics in WABS lympho-
blasts, we performed DNA fiber assays. This revealed a subtle, but
consistent decrease of replication fork speed (Fig. 2d). In
conclusion, WABS patient cells display CPT-induced chromoso-
mal breaks, as well as spontaneous DNA damage signaling, DNA
replication stress and cohesion loss.
DDX11 missense alleles reduce protein stability. Remarkably,
all patients have at least one hypomorphic variant (missense
variant or in frame indel), which may generate a partially active
protein. Indeed, we detected faint but specific DDX11 protein
bands on western blot (Fig. 3a). Whereas DDX11 mRNA levels of
the different WABS cells were all largely comparable to controls
(Fig. 3b), treatment with the proteasome inhibitor marizomib
partially restored DDX11 protein levels (Fig. 3c), indicating that
DDX11 protein stability is typically reduced in WABS cells.
To test whether this is caused by the identified missense
mutations, we overexpressed cDNAs representing the newly
identified weak DDX11 alleles in WABS01 fibroblasts (Fig. 3d).
In agreement with the unaffected mRNA levels in WABS cells, the
mutant DDX11 cDNAs exhibited relatively normal mRNA
stability, determined by quantifying the reduction of DDX11
mRNA upon actinomycin-mediated transcription blockage (Sup-
plementary Fig. 3a). We then treated these cells with cyclohex-
imide, which stabilizes mRNA and at the same time blocks
translation, to assess protein stability. This revealed that while
DDX11 is a rapidly degraded protein already, DDX11 mutants
showed further reduced protein stability (Fig. 3e and Supplemen-
tary Fig. 3b). The c.419G>A (p.R140Q) variant, found in WABS03,
has a minor allele frequency of 0.002 and was predicted to be
deleterious by two out of four pathogenicity predicting tools (e.g.
Mutation Taster and PolyPhen-2). Overexpression of this variant
demonstrated only slightly reduced protein stability. Blocking
protein degradation by marizomib or by the lysosome inhibitor
chloroquine revealed that the DDX11 mutants are more rapidly
stabilized than wild type (wt) DDX11, while R140Q shows a small
increase (Fig. 3f, g and Supplementary Fig. 3c, d). So, while we
could confirm that different WABS-associated DDX11 missense
mutations reduced protein stability, explaining the very low levels
of DDX11 protein expression in patient-derived cells, we could
only partially confirm that DDX11 R140Q is the disease-causing
mutation in the paternal allele of WABS03.
We used the same WABS cell lines to evaluate wt and mutant
DDX11 protein localization using immunofluorescence (Fig. 3h).
Whereas wt DDX11 shows nuclear localization, several mutants
(G57R, S857R, and C705Y) show substantially increased
cytoplasmic retention and a more punctuate staining pattern.
However, the R140Q mutant localized to the nucleus in a manner
similar to wt DDX11.
Despite alterations in their intracellular localizations, the fact
that cDNA overexpression of the mutants was able to restore
DDX11 protein expression to some extent, suggested that WABS
cells from different origins retain residual levels of DDX11
functionality. To further test this, we measured sister chromatid
cohesion upon transfection of WABS cells with DDX11 siRNA
(Fig. 3i and Supplementary Fig. 4a). Although the extent of
Table 2 Currently reported DDX11 variants in WABS patients.
Variant 1 Variant 2
DNA Protein DNA Protein
v.d. Lelij et al.1 WABS01 c.2271+2T>C p.C754P fs*9 c.2689-2691del p.K897del
Capo-Chichi et al.6 3 patients c.788G>A p.R263Q c.788G>A p.R263Q
Bailey et al.5 1 patient c.638+1G>A splice site c.1888delC p.R630F fs*23
Eppley et al.7 2 patients c.1523T>G p.L508R c.1949-1G>A splice site
Alkhunazi et al.4 Patient 1 c.606delC p.Y202* c.2372G>A p.R791Q
Patient 2 c.1133G>C p.R378P c.1133G>C p.R378P
Patient 3+4 c.2576T>G p.V859G c.2576T>G p.V859G
Patient 5 c.2638dupG p.A880G fs*94 c.2638dupG p.A880G fs*94
Bottega et al.8 2 patients c.2507T>C p.L836P c.907-920del p.K303E fs*22
Rabin et al.9 2 patients c.1763-1G>C splice site c.1763-1G>C splice site
Present study WABS02 c.169G>C p.G57R c.2692-1G>A p.K897_F898ins25
WABS03 c.1403dupT p.S469V fs*31 c.419G>A p.R140Q
WABS04 c.1930G>A p.V644M c.2114G>A p.C705Y
WABS05+WABS06 c.2571C>A p.S857R c.1672C>T p.R558*
WABS07+WABS08 c.1946-1948del p.G650del c.1763-1G>C p.G588A fs*6
Note that the pathogenicity of variant c.419G>A (p.R140Q) in patient WABS03 is uncertain.
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DDX11 mRNA knockdown was modest in some cases, the level
of sister chromatid cohesion loss was consistently enhanced by
DDX11 siRNA treatment. In summary, multiple patient-derived
DDX11 mutations cause destabilization and/or mis-localization
of the DDX11 protein. DDX11 is still partially active in the
investigated WABS patient-derived cell lines, possibly indicating
that complete loss of DDX11 is incompatible with cellular fitness
or embryonic survival as is the case in mice15,16.
DDX11 loss impairs growth and DDR in a p53-dependent
fashion. We then used CRISPR-Cas9 to delete DDX11 in human
diploid RPE1-TERT cells, using previously generated RPE1-
TetOn-Cas9 and RPE1-TetOn-Cas9-TP53KO clones53. Analysis
of multiple DDX11 guide RNA (gRNA) transfected clones
revealed only one clone out of eleven with bi-allelic DDX11
inactivation in TP53-wt cells, whereas four out of eight clones in
the TP53KO background contained a frame-shift inducing indel
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in both alleles (Fig. 4a). This difference might relate to p53-
dependent effects on CRISPR efficiency54,55 but since
DDX11KO in wtTP53 cells caused elevated p53 protein levels
(Fig. 4b) and reduced growth rate (Fig. 4c), it appears more
likely that loss of DDX11 activates p53, hampering survival of
DDX11 knockout cell lines. In line with this hypothesis, we
observed increased expression of the p53 target gene p21 both in
siDDX11 and in DDX11KO cells (Fig. 4d), and, importantly,
transfection with p53 siRNA rescued the proliferation of
DDX11KO cells (Fig. 4c). In conclusion, DDX11 inactivation
triggers a p53-dependent proliferation delay under normal
growth conditions.
100
100
DDX11 qRT-PCR
50
R
el
at
ive
 to
 L
N
9S
V 
(%
)
0
LN
9S
V
HF
-1
HF
-2
DDX11
Tubulin
DDX11
Tubulin
DDX11
DDX11
WT G57R
DAPI
72%
80
60
%
 o
f m
et
ap
ha
se
s
40
20
siRNA: NT DDX11 NT DDX11 NT DDX11 NT DDX11 NT DDX11
RPE1-hTERT
43% 9% 43% 63%
1–4 RR
5–10 RR
>10 RR
RR + PCS Normal
cohesion
Railroad
(RR)
Premature
chromatid
separation
(PCS)
Total PCS
Knockdown
efficiency:
Cdc6
Tubulin
LN
9S
V s
iNT
LN9SV
LN
9S
V s
iDD
X1
1
WA
BS
01
W
AB
S0
1
WT WT G5
7R
R1
40
Q
S8
57
R
V6
44
M
C7
05
Y
WT G5
7R
S8
57
R
R1
40
Q
V6
44
M
C7
05
Y
S857RR140Q V644M C705Y
WT
S8
57
R
R1
40
Q
V6
44
M
C7
05
Y WT
S8
57
R
R1
40
Q
V6
44
M
C7
05
Y
WA
BS
03
WA
BS
04
WA
BS
05
WA
BS
08
WABS04 WABS05 WABS08
WA
BS
01
WABS01 + DDX11 mutants
WA
BS
03
WA
BS
04
WA
BS
05
WA
BS
08
WABS01 WABS03 WABS04 WABS05
50
100
50
100
50
Marizomib: – + – + – + – +
100
0.4
Cycloheximide ChloroquineMarizomib
0.2
R
el
at
ive
 D
D
X1
1 
le
ve
ls
u
po
n 
tre
at
m
en
t
0
4
3
1
2
R
el
at
ive
 D
D
X1
1 
le
ve
ls
u
po
n 
tre
at
m
en
t
0
3
1
2
R
el
at
ive
 D
D
X1
1 
le
ve
ls
u
po
n 
tre
at
m
en
t
0
50
50
a b
c
d
e f g
h
i
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18066-8 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:4287 | https://doi.org/10.1038/s41467-020-18066-8 |www.nature.com/naturecommunications 7
Similar to WABS cells, RPE1-DDX11KO cells showed
increased sensitivity to CPT, as well as to the DNA polymerase
inhibitor aphidicolin and PARPi talazoparib (Supplementary
Fig. 5a). Moreover, analysis of 53BP1 foci and γH2AX foci
revealed increased DNA damage signaling (Supplementary
Fig. 5b) and we detected an increased number of asymmetric
forks (Supplementary Fig. 5c). Finally, DDX11 deficient cells
exhibited increased sensitivity to the RAD51 inhibitor BO-2
Fig. 3 DDX11 missense alleles reduce protein stability. a WABS fibroblasts were analyzed for DDX11 protein levels by western blot. As control, LN9SV
fibroblasts were transfected with non-targeting or DDX11 siRNA for two days. The asterisk indicates a non-specific band. A representative of three
independent experiments is shown. b RNA from WABS fibroblasts and three control fibroblasts was analyzed for DDX11 expression by qRT-PCR in five
independent experiments. c WABS cells were treated with 500 nM marizomib for 5 h to inhibit proteasomal degradation and analyzed by western blot.
Cdc6 was included as a positive control. A representative of two independent experiments is shown. d WABS01 cells were stably transfected with cDNAs
encoding either WT-DDX11 or several patient-derived DDX11 mutants and DDX11 protein levels were analyzed by western blot. A representative of three
independent protein analyses is shown. e Cells were treated with 62.5 µg/mL cycloheximide for 3 h to inhibit protein synthesis and analyzed by western
blot. Bands were quantified using Image Lab software, normalized to tubulin and the decrease of DDX11 protein levels during the cycloheximide treatment
was determined for each mutant. f, g Similarly, protein degradation was inhibited by treatment with marizomib (500 nM, 5 h) or with the lysosome
inhibitor chloroquine (25 µM, 24 h). Increase of DDX11 protein levels during the treatment was determined for each mutant. Examples of western blots that
were quantified in (e), (f), and (g) are provided in Supplementary Fig. 3b–d. h DDX11 expression and localization in WABS01 cells expressing different
DDX11 versions were assessed by immunofluorescence. Two independent experiments were performed, showing comparable results. i RPE1-hTERT cells
and four WABS fibroblasts were transfected with indicated siRNAs (day 1 and day 4) and analyzed for cohesion defects seven days after the first
transfection. Accompanying qRT-PCR (Supplementary Fig. 4a) was performed to determine knockdown efficiency, which is indicated as percentage in the
figure. Per condition, in total 150 metaphases from three independent experiments were assessed.
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inhibitor BO-2 (10 µM). Growth was monitored using IncuCyte software. In total six replicates from two independent experiments are shown.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18066-8
8 NATURE COMMUNICATIONS |         (2020) 11:4287 | https://doi.org/10.1038/s41467-020-18066-8 | www.nature.com/naturecommunications
(Fig. 4e), indicating that proliferation of DDX11 deficient cells is
highly dependent on continuous DNA damage repair via a
RAD51-dependent pathway.
No redundant role of DDX12p in cohesion and proliferation.
Considering high sequence similarities, we aimed to investigate
whether the pseudogene DDX12p, which is absent in mice, could
partially compensate for loss of DDX11. We designed qRT-PCR
primers that specifically amplify DDX11 or DDX12p, utilizing a
small difference in the sequences of exon 17 of DDX11 and
DDX12p, respectively (Supplementary Fig. 4b). This revealed that
the DDX11 siRNA used here also depletes DDX12p mRNA
(Fig. 5a), providing a possible explanation for increased cohesion
loss in WABS cells upon treatment with this siRNA. Interestingly,
WABS cells express DDX12p mRNA at comparable levels as
control cells (Fig. 5b). We constructed specific DDX11 or
DDX12p knockout cells, using gRNA target sites close to an
intronic region in DDX11 which is absent in DDX12p (Fig. 5c).
This enables specific amplification of both DDX11 and DDX12p
genomic DNA by specific forward primers, either inside (DDX11,
blue arrow) or spanning this region (DDX12p, red arrow). We
generated a panel of six cell lines (two clones for each gRNA) that
is described in detail in Supplementary Fig. 6. Importantly, we
found that loss of DDX11, but not of DDX12p, impairs cellular
proliferation (Fig. 5d) and induces cohesion loss (Fig. 5e) in
RPE1 cells. To determine the full length human DDX12p mRNA
sequence, unavailable through validated genomic databases, we
cloned and sequenced multiple PCR fragments (Supplementary
Fig. 7a) and also performed a 3’RACE PCR (Supplementary
Fig. 7b). This revealed that an intact start codon, all exons and a
poly-A tail can be found in DDX12p transcripts, although some
exon-skipping isoforms were also detected. Apparently an intact
DDX12p ORF might exist. However, we also found a 5 bp dele-
tion in exon 8 leading to a predicted DDX12p protein of only 300
amino acids, lacking large parts of the putative helicase domain of
DDX11 yet containing the region homologous to the Timeless
binding domain of DDX11 (186–232)41 (Supplementary Fig. 7a).
In conclusion, while DDX12p encodes an RNA product that is
processed by RNA splicing and poly-adenylation, we found no
evidence that DDX12p (m)RNA encodes a protein that func-
tionally compensates for DDX11 helicase loss.
DDX11 deficient cells do not tolerate G4 stabilization. Anti-
parallel G-quadruplex (G4) structures, four-stranded structures
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formed by guanine-rich nucleic acids, were previously reported to
be a particular DDX11 substrate in vitro22. Therefore, we inves-
tigated the effects of two different G4-stabilizing compounds,
quarfloxin (CX3543) and CX546156. In both RPE1-DDX11KO
cells and in WABS cells, G4 stabilization significantly inhibited
proliferation (Fig. 6a, b and Supplementary Fig. 8a) and caused
the accumulation of chromosomal breaks (Fig. 6c). We also
observed increased DNA damage signaling, indicated by 53BP1
foci (Fig. 6d). Strikingly, G4 stabilization was sufficient to induce
cohesion loss in RPE1 cells and aggravated cohesion defects in
WABS cells (Fig. 6e). WABS01+wtDDX11 cells did not show
cohesion loss upon G4 stabilization, suggesting that over-
expression of DDX11 confers cellular resistance to these com-
pounds. Lastly, we assessed replication fork dynamics by a DNA
fiber assay. Quarfloxin had no clear effect on origin firing (Sup-
plementary Fig. 9a), but we observed reduced fork speed (Fig. 6f)
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and an increased amount of asymmetric fibers (Supplementary
Fig. 9b), suggesting increased stalling of DNA replication forks.
Since both quarfloxin and CX5461 may inhibit ribosomal DNA
(rDNA) transcription57,58, we asked whether repressed ribosomal
gene expression as such contributes to the observed toxicity in
WABS cells. To this end, we assessed the effect of the rDNA
binding agent Bmh21, which causes blockage of RNA polymerase
I and degradation of its catalytic subunit59,60. At concentrations
that clearly block rDNA transcription (Supplementary Fig. 8b),
WABS01 cells were not sensitive to Bmh21 (Supplementary
Fig. 8c). Therefore, we conclude that the sensitivity of DDX11
deficient cells to quarfloxin and CX5461 primarily relates to
stabilization of G4s or similar DNA structures by these drugs.
Together, our findings suggest that unresolved, putative
DDX11 substrates by themselves are a source of both DNA
damage and sister chromatid cohesion loss, possibly at DNA
replication forks.
Distinct roles of FANCJ and DDX11 in G4 stabilizer responses.
We wondered how the role of DDX11 in G4 stabilizer protection
compared to the related Fe-S helicase FANCJ. We generated
FANCJ knockouts in RPE1-TP53KO and in RPE1-TP53KO-
DDX11KO cells (Fig. 7a). As reported previously52, double
DDX11 FANCJ knockout resulted in a synergistic growth defect
even in the absence of genotoxic agents (Fig. 7b), suggesting roles
for DDX11 and FANCJ in normal proliferation. FANCJKO had a
larger effect on MMC response than DDX11KO, both in recovery
from transient exposure (Fig. 7c) and during continuous exposure
(Fig. 7d). Combined depletion further enhanced MMC sensitivity,
indicating that FANCJ and DDX11 function in separate repair
pathways, as previously hypothesized52.
FANCJKO cells also displayed increased sensitivity for the
small-molecule G4 stabilizer pyridostatin, albeit less than
DDX11KO cells. Surprisingly, treatment with quarfloxin and
CX5461 hardly affected FANCJKO cells (Fig. 7c, d). A
comparison of patient-derived fibroblasts showed high MMC
sensitivity in FANCJ patient cells, whereas WABS cells were most
sensitive to quarfloxin and CX5461 (Supplementary Fig. 10). The
observed drug sensitivities of FANCJKO and DDX11KO cells
coincided with DNA damage signaling, as detected by γH2AX
and TP53BP1 focus formation (Fig. 7e, f). In addition, DDX11KO
cells exhibited increased DNA damage signaling in untreated
conditions, which was not detected in FANCJKO cells but was
further exacerbated in double knockout cells. This suggests that
FANCJ functions in a different pathway as DDX11 to mitigate
DNA damage arising from endogenous sources.
We further investigated FANCJ- and DDX11-dependent drug
responses by transient crRNA transfection in Cas9 expressing
cells. This approach was validated with a lethal crRNA, which
efficiently blocked cell growth (Supplementary Fig. 11a), and by
indel analysis (Supplementary Fig. 11b). As expected, acute
DDX11 knockout sensitized to quarfloxin, CX5461, pyridostatin
and MMC, whereas FANCJ depletion sensitized to MMC and
possibly also to pyridostatin (Supplementary Fig. 11c, d).
However, no effect of FANCJ knockout on quarfloxin or
CX5461 sensitivity was observed. Targeting two other putative
G4 helicases, the RecQ family members BLM and WRN61,
revealed no effect of WRN, whereas targeting BLM mildly
sensitized to all compounds and resulted in additive sensitivity in
DDX11KO cells (Supplementary Fig. 11c–e). Together, we
conclude that, of the disease-linked DNA helicases tested here,
DDX11 is the dominant DNA helicase resolving substrates that
are targeted by the G4 stabilizers quarfloxin and CX5461.
Sister chromatid cohesion requires DDX11 helicase activity. To
further investigate the role of DDX11 helicase activity in sister
chromatid cohesion, we introduced DDX11-K50R, a previously
described DNA helicase-dead mutant22, into WABS01 cells and
TP53KO-DDX11KO RPE1 cells (Fig. 8a). Whereas wtDDX11
overexpression rescued sister chromatid cohesion loss in DDX11
deficient cells, overexpression of DDX11-K50R had no protective
effect (Fig. 8b). Furthermore, DDX11-K50R could not restore
DNA replication fork speed (Fig. 8c) or resistance to multiple
G4 stabilizers (Supplementary Fig. 12a), talazoparib and CPT
(Supplementary Fig. 12b) in DDX11KO RPE1 cells. These find-
ings indicate that the helicase activity is essential for DDX11
function.
The observation that WABS cells possess low expression of
DDX11 and residual DDX11 activity predicts that some patient-
derived DDX11 missense alleles are hypomorphic but still
functional when overexpressed. Indeed, we found that three
patient-derived missense mutants could at least partially correct
the cohesion loss in WABS01 cells: R140Q, V644M, and S857R
(Fig. 8d). Two others, G57R and C705Y, showed no activity,
indicating these are null-alleles. The C705Y allele originates from
WABS04, indicating that the other allele, DDX11 V644M is
hypomorphic. The G57R allele is derived from patient WABS02.
The second DDX11 allele of WABS02 harbors a splice-site
mutation resulting in retention of intron 26 and an in-frame
insertion of 25 amino acids at DDX11 C-terminus, which may
yield a partially functional DDX11 protein. We noticed that G57R
is located close to the Walker A helicase motif I, whereas C705Y
is located in helicase motif IV (Fig. 8e). Both regions are highly
conserved between different DDX11 orthologues and, to a lesser
extent, between other FeS-cluster containing SF2 helicases. This
suggests that DNA helicase activity is also impaired in these
mutants. Indeed, DDX11-C705Y showed impaired in vitro
helicase activity, while DDX11-R140Q acted similarly as WT
(Fig. 8f). Moreover, the quarfloxin sensitivity of WABS01
fibroblasts could be rescued by significantly overexpressing
patient-derived hypomorphic point mutants but not by
helicase-dead DDX11 point mutants (Supplementary Fig. 12c).
To prove the essential role of the DDX11 helicase domain in vivo,
we generated DDX11G57R/WT mice by oligonucleotide-directed
Fig. 6 DDX11 confers resistance to G-quadruplex stabilization. a Cells were cultured in 96-wells plates and treated with 200 nM quarfloxin or 500 nM
CX5461. Growth was monitored using IncuCyte software in three technical replicates. b WABS01, WABS05 and HSC93 control lymphoblasts were
continuously exposed to increasing concentrations quarfloxin or CX5461. After three population doublings of untreated cells, cells were counted and
plotted as percentage of untreated cells. Data from three independent experiments are shown. IC50 values from each dose-response curve were
determined using curve fitting and shown as averages ± standard deviations. c Cells were treated with 200 nM quarfloxin or 500 nM CX5461 for 24 h and
chromosomal breaks were scored in 50 metaphase spreads per condition. d Cells were treated as indicated and 53BP1 staining was analyzed by
immunofluorescence. In total at least 85 cells per condition were counted for two independent experiments. Boxes extend from the 25th to the 75th
percentile, whiskers from the smallest to the largest value, lines indicate the median. e Cells were treated with 200 nM quarfloxin or 500 nM CX5461 for
24 h and cohesion defects were analyzed in 50 metaphases per condition. f Cells were treated with 200 nM quarfloxin (Q) for 24 h and assessed with a
DNA fiber assay using a double labeling protocol. In total at least 165 fibers were scored per condition in two independent experiments. The example track
represents an ongoing fork. Black lines indicate the mean. P-values were calculated by a non-parametric one-way ANOVA test.
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gene modification (Fig. 8g). Intercrossing of these mice did not
yield any homozygous DDX11G57R/G57R offspring among 87
heterozygous and 78 wild-type animals. Genotyping of prenatal
stages revealed lethality before day 10 of embryonic development,
indicating that the presumed helicase-dead DDX11-G57R is a
null allele (Fig. 8g). Taken together, we conclude that the DNA
helicase domain of DDX11 facilitates normal DNA replication, to
prevent DNA damage and cohesion loss, presumably by resolving
G4 structures that arise when replication forks travel through G-
rich regions.
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Discussion
We show here that WABS cells possess residual DDX11 activity
and find that several patient-derived DDX11 mutants encode a
functional but unstable protein. Although most published DDX11
mutants were not functionally studied, most if not all WABS
patients appear to harbor at least one pathogenic mutation that
could potentially yield a protein product with partial activity.
Indeed, DDX11-R378P has reduced protein stability4, whereas
DDX11-R263Q, although located in the FeS cluster and dis-
playing reduced helicase activity, could still unwind a forked
duplex structure at higher concentrations6. These observations,
combined with the embryonic lethality of DDX11 knockout
mice15,16, the lack of functional redundancy of the pseudogene
DDX12p and the fact that DDX11 knockout causes severe, p53-
dependent growth inhibition in human RPE1 cells, suggest that
minimal DDX11 protein expression is essential to support cellular
fitness and normal human development. Notably, caution is
needed in the diagnosis of disease-causing DDX11 mutations, for
instance when prenatal testing for WABS would be intended.
Mutations with an intermediate effect on DDX11 protein func-
tion are common in WABS patients but are difficult to distinguish
from rare, non-pathogenic DDX11 variants. For example,
DDX11-R140Q could rescue sister chromatid cohesion in
WABS01 cells when overexpressed. It showed reduced protein
stability in some experiments but the effect was mild. Never-
theless, patient WABS03 is undoubtedly a WABS patient based
on the rescue of cellular defects by the introduction of wild-type
DDX11, and we found no other intronic or exonic mutation in
the relevant DDX11 allele that correctly segregated with the
inheritance of the disease. DDX11 mRNA expression in WABS03
cells was similar to that observed in control cells, providing no
evidence for impaired DDX11 gene promoter function.
With the seven cases of this study, a total of 23 WABS cases
have now been described. Whereas WABS clinically resembles
FA, the anemia phenotype is lacking. WABS also resembles NBS,
but evidence for severe immune deficiency and early onset of
leukemia or other cancers observed in NBS patients has not been
found in WABS so far. The oldest WABS patient reported,
WABS04, died at the age of 64 with no evidence of cancer. The
clinical spectrum of WABS is heterogeneous and also shows
considerable overlap with the cohesinopathies Roberts Syndrome
(RBS) and Cornelia de Lange Syndrome (CdLS), with the most
notable exceptions being limb reductions, which are not found in
WABS (although clinodactyly is observed), and abnormal skin
pigmentation including café-au-lait spots, which are not found in
RBS and CdLS1,4–9. WABS has been classified as a cohesinopathy
because of the spontaneous railroad chromosomes and PCS that
are observed in metaphase spreads. This characteristic is also
found in RBS, but not in CdLS, which may be explained by the
milder impact of CdLS mutations on cohesin function. In yeast,
the distinct processes regulated by cohesin were shown to be
differentially affected by modulating cohesin levels62. The clinical
overlap between RBS and CdLS could be attributed to over-
lapping effects of reduced cohesion on gene transcription,
whereas differences might relate to additional defects in mitotic
sister chromatid cohesion and DNA repair, typical for RBS63.
Although most cohesinopathy-derived cells display some level of
increased genotoxic sensitivity, the MMC-induced breakage
phenotype is particularly pronounced in WABS cells, reported in
most (except one4) published cases and in the three WABS cases
in this study in which chromosomal breakage was investigated.
Moreover, drug toxicity patterns, in particular the sensitivity to
PARPi, indicate either impaired homologous recombination in
WABS cells52 or pinpoint to increased sensitivity to DNA repli-
cation stress64. In line with these observations, multiple of the
clinical manifestations of WABS overlap with those observed in
chromosomal instability syndromes such as FA65 and NBS66.
Thus, WABS can be classified as both a cohesinopathy and a
chromosomal breakage syndrome, even though evidence for
increased cancer risk is missing.
Our data show that the sensitivity of DDX11 deficient cells to
quarfloxin and CX5461 exceeds that of cells deficient for other
putative G4 helicases FANCJ, BLM, and WRN. By contrast, it has
been reported that the G4 stabilizer telomestatin (TMS)67 is toxic
to FANCJ deficient cells, whereas DNA damage inflicted by TMS
is hardly affected by DDX1168. A possible explanation for this
difference could be that like G4 helicases, also G4 stabilizers act
on a specific subset of G4s, depending on their architecture and/
or subcellular localization69. While the exact DNA substrate
specificities of quarfloxin are incompletely understood, some
observations are noteworthy. Quarfloxin stabilizes different var-
iants of G4 structures56, but accumulates in the nucleolus in cells
and has a preference for ribosomal DNA and promoter sequen-
ces58. TMS on the other hand stabilizes the formation of telo-
meric G4 structures, thereby inhibiting telomerase70.
Interestingly, studies in S. pombe suggest that telomeric G4 motifs
form intramolecular G4s, whereas in ribosomal DNA pre-
dominantly intermolecular G4s are formed71. Considering that
in vitro experiments revealed that DDX11 preferentially resolves
bi-molecular over uni-molecular G4s22,68 and DDX11 was pre-
viously reported to reside in the nucleolus72, the observed sen-
sitivity of DDX11 deficient cells to quarfloxin may originate from
unresolved nucleolar G4s.
Apart from their roles in promoting sister chromatid cohesion
and preventing DNA breaks in unperturbed conditions, Chl1 and
DDX11 are also involved in the response to DNA replication
stress14,17,25,38,73–75, a function probably executed by promoting
RPA loading and Chk1 activation38,75. It has been proposed that
the DNA helicase activity of yeast Chl1 is only required for
replication fork progression and the response to fork stalling,
Fig. 8 DDX11 helicase activity supports cohesion, DNA replication and embryonic survival. a WABS01 cells (left panel) and RPE1-TP53-DDX11KO cells
(right panel) were stably transduced with empty vector (EV), wtDDX11 or DDX11-K50R and analyzed by Western blot. l.e. long exposure. A representative of
two independent protein analyses is shown. b Cells were analyzed for cohesion defects. Per condition, in total 100 metaphases from two independent
experiments were assessed. c Replication fork speed was assessed with a DNA fiber assay using a double labeling protocol. In total at least 200 fibers were
scored per condition in two independent experiments. The example track represents an ongoing fork. Blue dots, DDX11 proficient; red dots, DDX11 deficient.
Black lines indicate the mean. P-values were calculated by a non-parametric one-way ANOVA test. dWABS01 cells, stably transfected with different DDX11
mutants, were analyzed for cohesion defects. Per condition, in total 150 metaphases from three independent experiments were assessed. e Alignment of
different DDX11 orthologues (top) and related SF2 DNA helicases (bottom). Conserved motifs are indicated. Arrows point at the positions of K50R, G57R,
and C705Y mutations. f In vitro DNA helicase assay of patient-derived DDX11 mutants. Purified, recombinant Flag-tagged proteins were analyzed by western
blot (left). Proteins were incubated at increasing concentrations with a fluorescently labeled forked DNA substrate. Helicase reaction products were resolved
by gel electrophoresis. Percentage of displaced DNA was determined using Image-J software. Right panel: quantification from three independent
experiments. g DDX11-G57R heterozygous mice were generated by oligonucleotide-directed gene modification in mouse embryonic stem cells substituting
glycine codon 57 for an arginine codon (C>G substitution). Subsequent intercrossing of heterozygous mice failed to produce homozygous offspring.
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whereas its role in sister chromatid cohesion was suggested to be
helicase-independent but relies on interaction with Ctf436.
Importantly, however, we show that the DNA helicase function of
human DDX11 is not only required to prevent lethal DNA
damage in response to G4 stabilizing drugs but also for sister
chromatid cohesion, in line with observations in chicken DT40
cells43. Besides the previously characterized helicase-deficient
mutant K50R76, also two patient-derived mutations in or near
conserved helicase motifs (G57R and C705Y) impair the rescue of
cohesion defects in DDX11 deficient cells. Importantly, hetero-
zygous G57R knock-in mice failed to produce homozygous G57R
offspring due to early onset embryonic lethality, further sug-
gesting that G57R DDX11 is a null allele and the helicase domain
is crucial for development. We thus propose that the require-
ments of the DDX11 helicase function for both DNA repair and
sister chromatid cohesion are inextricably linked.
Why does loss of DDX11 result in cohesion loss? Based on its
interaction with Fen1, it has been suggested that Chl1 allows
efficient maturation of Okazaki fragments, facilitating the sub-
sequent loading of cohesin as the fork progresses19,20,37. Another
model proposed that Chl1 supports the ability of cohesin rings,
which are already bound to double-stranded DNA, to capture a
second ssDNA molecule77. DDX11 deficiency might also result in
broken replication forks, which require the removal of cohesin for
a rapid repair process, at the cost of cohesion loss53. Based on the
helicase dependency in our experiments and the known interac-
tion with a number of proteins involved in lagging strand
replication20,38,39,41, DDX11 may function primarily to resolve
complex secondary structures in the lagging strand. Possibly, the
binding of DDX11 to several replisome components, such as
Timeless, facilitates the correct positioning of DDX11 to unwind
its substrates. In this model, the observed cohesion loss, replica-
tion delay, DNA damage and growth inhibition resulting from
DDX11 depletion are linked to the same process: failure to resolve
secondary DNA structures in the lagging strand, leading to fork
stalling and DNA breaks. This may hamper cohesin loading and
trigger cohesin removal to facilitate DNA repair. It will be
important to further unravel which exact structures are resolved
by DDX11 and targeted by drugs such as quarfloxin and CX5461,
and the context in which these occur in cells.
Methods
Compounds. The following drugs were used: camptothecin (CPT), actinomycin D,
cycloheximide, marizomib, chloroquine, Bmh21, BO-2, (all Sigma-Aldrich), aphi-
dicolin (Santa Cruz), talazoparib (Axon Medchem), quarfloxin (CX-3543, Adooq
Bioscience) and CX-5461 (Selleckchem).
Samples and sequencing. The research on patient material was carried out after
approval by the institutional review board of the VU University Medical Center,
adhered to local ethical standards. Appropriate informed consent was obtained
from patients or from parents/relatives as applicable. For DNA diagnosis, DNA
was extracted from whole blood or EBV-transformed lymphoblastoid cell lines.
Genomic DNA was isolated using the QIAmp blood kit (Qiagen). Direct Sanger
sequencing of DDX11 coding exons was performed for WABS02 and WABS03.
WABS05 was analyzed with a custom Haloplex (Agilent) kit targeting the coding
regions of all known cohesinopathy genes using 200 ng of genomic DNA to obtain
sequencing libraries. Samples tagged with a unique barcode and pooled before 150
bp pair-ended sequencing on the Illumina Miseq platform. SureCall software
(version 2.0, Agilent) was used to detect variants. WABS03 and WABS05 primary
fibroblasts were both analyzed by RNA sequencing upon treatment with cyclo-
heximide. The cDNA was synthesized with random hexamers and barcoded DNA
adapters were ligated to both ends of the double-stranded cDNA and subjected to
PCR amplification. The resultant library was sequenced on an Illumina HiSeq 2000.
Sample WABS04 was enriched for the whole exome using Nimblegen Exome V.3 oligo
library kit, barcode-tagged and pooled with a total of six samples, and sequenced on one
HiSeq 2000 illumina lane using the 100 paired-end protocol. Exome data analysis was
performed using genome analysis tool kit (GATK; www.broadinstitute.org/gatk). For
WABS07 and WABS08, whole exome sequencing was performed on DNA, isolated
from amniotic fluid cells. Genomic DNA was extracted according to standard proce-
dures and enriched with Agilent Sureselect Clinical Research Exome (CRE) Capture.
Samples were run on the HiSeq 4000 (101 bp paired-end, Illumina). On average, 50
million reads per exome and a mapped fraction above 98% were obtained. Average
coverage is approximately 50 fold. Reads were mapped to the genome using BWA (bio-
bwa.sourceforge.net). Variant detection was performed by GATK. Analysis of variants
(VCF file) was performed in Alissa Interpret (Illumina) by filtering on quality (read
depth ≥10), minor allele frequency (≥1% in 200 alleles in dbSNP, ESP6500, the 1000
Genome project or the ExAC database), location (within an exon or first/last 10 bp of
introns). Variants were further selected based on three inheritance models (de novo
autosomal dominant, autosomal recessive and X-linked recessive). Of note, a hemi-
zygous variant of unknown significance (VUS) in the X-linked Duchenne gene DMD,
most likely not pathogenic, was found in WABS07 and WABS08. Validation of the
identified DDX11 mutations was performed by Sanger sequencing.
3′RACE PCR. The second generation 5′/3′ RACE Kit (Roche) was used to amplify
the 3′UTR of DDX11 and DDX12p from RPE1 cDNA, by using a non-specific
forward primer and a mix of three tagged oligo dT primers. The resulting PCR
product was used as a template for a second PCR reaction, using a forward primer
specific for DDX11 or DDX12p and a reverse primer that anneals to the tag. The
resulting PCR fragments were cloned into zero-blunt plasmids and sequenced
using specific primers for DDX11 or DDX12p. Primer sequences are listed in
Supplementary Table 1.
Construction of cell lines and cell culture. RPE1-hTERT cells (American tissue
culture collection) and SV40 transformed fibroblasts, including WABS011,
WABS02, WABS03, WABS04, WABS05, WABS08, FANCJ patients 1 and 2
(VU1414F and VU030F78) and LN9SV control79, were cultured in Dulbecco’s
Modified Eagles Medium (DMEM, Gibco), supplemented with 10% FCS, 1 mM
sodium pyruvate and antibiotics. Epstein-Barr virus (EBV) transformed lympho-
blasts, including WABS01-L, WABS03-L, WABS04-L, WABS05-L, RBS-L (ESCO2
deficient), VU867-L (deficient in both FANC-A and FANC-M)80, and HSC93
control81, were cultured in Roswell Park Memorial Institute (RPMI, Hyclone)
supplemented with 10% FCS, 1 mM sodium pyruvate and antibiotics.
WABS03-L, WABS04-L, and WABS05-L were functionally complemented by
transfection of pMEP4 plasmid (Invitrogen) expressing wild type DDX11
(transcript variant 1, NM_030653.4) and selected with 70 µg/ml hygromycin-B.
WABS02 and WABS08 fibroblasts were stably transfected with pIRES-Neo
plasmids containing wtDDX11 or (in the case of WABS01) different DDX11
mutants, that were constructed using overlap extension PCR, and selected with 700
µg/mL G418. For DDX11-K50R studies, RPE1-TP53KO-DDX11KO and
WABS01 cells were transduced with Lenti-CMVie-IRES-Blast (gift from Ghassan
Mouneimne (Addgene plasmid #119863)82 and selected with 15 µg/mL Blasticidin.
CRISPR-Cas9 was used to construct clonal and transient knockouts in
RPE1 cells. The generation of RPE1-hTERT_TetOn-Cas9_TP53KO is described
before53. Briefly, Cas9 cDNA was cloned into the pLVX-Tre3G plasmid (Clontech)
and lentiviral Tre3G-Cas9 and Tet3G particles were produced in HEK293T cells
using the Lenti-X HT packaging system (Clontech). Transduced cells were selected
with 10 µg/mL puromycin and 400 µg/mL G418. Cells were treated with 100 ng/mL
doxycycline (Sigma-Aldrich) to induce Cas9 expression and transfected with
10 nM synthetic crRNA and tracrRNA (Dharmacon or IDT) using RNAiMAX
(Invitrogen). The following crRNA sequences were used: TP53 CCATTGTTC
AATATCGTCCG, DDX11/12p CTTTGGCAAGGATGTTCGGC,DDX11 specific
GGCTGGTCTCCCTTGGCTCC, DDX12p specific GCTTATCAACGACC
GCTGCG, OR10A7 AGAAGAGGGACACCACAATG, POLR2L ACAAGTGGGA
GGCTTACCTG, FANCJ#1 AGATTACTAGAGAGCTCCGG, FANCJ#2 TAACA
TCGAGGACTGTGCTC, BLM TACGGCCACAGCTAATCCCA, WRN, TAGG
AATTGAAGGAGATCAG. Indels were assessed by Sanger sequencing. To
specifically amplify DDX11 and DDX12p genomic regions surrounding gRNA
target sites, primers inside or spanning a DDX11 specific intronic region were
designed (Fig. 5c). Primer sequences are listed in Supplementary Table 1.
Proliferation assays. Lymphoblasts were seeded in T25 flasks with increasing drug
concentrations, and counted again when untreated cells reached approximately
three population doublings. IC50 values were determined using curve fitting
(www.ic50.tk). For adherent cells, the IncuCyte Zoom instrument (Essen
Bioscience) was used. RPE1 cells (1500/well) and fibroblasts (3000/well) were
seeded in 96-wells plates and imaged every 4 h with a ×10 objective. IncuCyte
software was used to quantify confluence from four non-overlapping bright field
images per well, for at least three replicate wells. Doubling time was calculated for
the period required to grow from approximately 30 to 70% confluence, using the
formula doubling time (h) = required time (h) * log(2)/(log(confluence endpoint
(%))− log(confluence starting point(%))). For clonogenic survival assays, cells were
counted and seeded at 1500 cells/well in 6-wells plates. Ten days after seeding, cells
were fixed in methanol, and stained in 0.5% crystal violet and 20% methanol.
siRNA experiments. For knockdown experiments, 25 nM siRNA (Dharmacon)
was transfected using RNAiMAX (Invitrogen). Sequences: non-targeting siRNA
UAAGGCUAUGAAGAGAUAC; siDDX11 GCAGAGCUGUACCGGGUUU,
CGGCAGAACCUUUGUGUAA, GAGGAAGAACACAUAACUA, UGUUCAA
GGUGCAGCGAUA; sip53 GAAAUUUGCGUGUGGAGUA, GUGCAGCUGUG
GGUUGAUU, GCAGUCAGAUCCUAGCGUC, GGAGAAUAUUUCACCCU
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UC; siUBB CCCAGUGACACCAUCGAAA, GACCAUCACUCUGGAGGUG,
GUAUGCAGAUCUUCGUGAA, GCCGUACUCUUUCUGACUA
qRT-PCR. Total RNA was extracted with the High Pure Isolation Kit (Roche) and
cDNA was prepared with the iScript cDNA Synthesis Kit (Biorad). Quantitative
reverse transcription polymerase chain reaction (qRT-PCR) was performed using
SYBR Green (Roche) on a LightCycler 480 (Roche). Levels were normalized to the
geometric mean of at least two housekeeping genes. Primer sequences are listed in
Supplementary Table 1.
Immunoblotting. Cells were lysed in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM
NaCl, 1% Triton X-100) with protease- and phosphatase inhibitors (Roche), except
for the WABS fibroblasts (Fig. 3a, c), which were directly scraped in sample buffer.
Proteins were separated by 3–8%, 4–15% or 8–16% SDS-PAGE (NU-PAGE or
BioRad) and transferred to immobilon-P membranes (Millipore). Membranes were
blocked in 5% dry milk in TBST-T (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.04%
Tween-20), incubated with primary and peroxidase-conjugated secondary anti-
bodies (DAKO Glostrup, Denmark; 1:10000) and bands were visualized by che-
moluminescence (Amersham). Antibodies used for detection are mouse-anti-
DDX11 (B01P, Abnova; 1:250–1:1000), goat-anti-β-actin (I-19, Santa Cruz;
1:1000), mouse-anti-α-tubulin (B-5-1-2, Santa Cruz #sc-23948; 1:2000), mouse-
anti-CDC6 (Santa Cruz #sc-9964; 1:500), mouse-anti-p62 (D5L7G, cell signaling;
1:1000), mouse-anti-Flag (M2, Sigma; 1:10000), mouse-anti-p53 (DO-1, Santa
Cruz #sc-126; 1:1000), mouse-anti-vinculin (H-10, Santa Cruz #sc-25336; 1:2000),
guinea pig anti-ESCO2 (1:50083). Uncropped western blots are provided in Sup-
plementary Fig. 13.
Analysis of cohesion defects and chromosomal breakage. Cells were incubated
with 200 ng/mL Demecolcin (Sigma-Aldrich) for 20 min (cohesion defect analysis)
or 30 min (chromosomal breakage analysis). Cells were harvested, resuspended in
0.075 M KCl for 20 min and fixed in methanol/acetic acid (3:1). Cells were washed
in fixative three times, dropped onto glass slides and stained with 5% Giemsa
(Merck). Cohesion defects or chromosomal breaks were counted in 50 metaphases
per condition on two coded slides. Analysis of breaks was described before84.
DNA fiber analysis. Cells were pulse-labeled with 25 µM chlorodeoxyuridine
(CldU) for 20 min, followed by 20 min 250 µM iododeoxyuridine (IdU).
Approximately 3000 cells were lysed in 7 µL spreading buffer (200 mM Tris-HCl
PH 7.4, 50 mM EDTA and 0.5% SDS). Fibers were spread on Superfrost micro-
scope slides, which were tilted ~15°, air-dried for several minutes and fixed in
methanol:acetic acid (3:1). DNA was denatured with 2.5 M HCl for 75 min, blocked
in PBS+ 1% BSA+ 0.1% Tween20 and incubated for 1 h with rat-anti BrdU
(1:500, Clone BU1/75, Novus Biologicals) and mouse-anti-BrdU (1:750, Clone B44,
Becton Dickinson). Slides were fixed with 4% paraformaldehyde for 10 min,
incubated for 1.5 h with goat-anti-mouse Alexa 488 and goat-anti-rat Alexa 594
(both 1:500, Life technologies) and mounted with Vectashield medium. Images of
DNA fibers were taken with a Zeiss AxioObserver Z1 inverted microscope using a
×63 objective equipped with a Hamamatsu ORCA AG Black and White CCD
camera. Fiber tract lengths were assessed with ImageJ and µm values were con-
verted into kilobases using the conversion factor 1 µm= 2.59 kb85,86.
Immunofluorescence. Cells were grown on cover slips, fixed in 2% paraf-
ormaldehyde for 15 min at RT and subsequently in 70% ice cold EtOH for 1 h.
Cells were permeabilized in 0,3% Triton X-100 for 5 min, blocked in 3% BSA and
0,3% Triton X-100 for 45 min, incubated with primary antibody for 1.5 h and
secondary antibody for 1 h at RT. Cells were mounted using ProLong™ Gold
Antifade Mountant with DAPI (Invitrogen) and cells were examined using fluor-
escence microscopy (Leica). Antibodies used: rabbit anti-DDX11 (ab204788,
Abcam), mouse-anti-yH2AX (Ser139, JBW301, Millipore), rabbit anti-53BP1
(Novus)
Flow cytometry. Cells were harvested, washed in PBS and fixed in ice cold 70%
EtOH. Cells were washed and resuspended in PBS with 1:10 PI/RNase staining
buffer (BD Biosciences) and analyzed by flow cytometry on a BD FACSCalibur
(BD Biosciences). Cell-cycle analysis was conducted with BD CellQuest software
(BD Biosciences).
Recombinant protein production and DNA helicase assay. DDX11-3xFlag (wild
type and the mutant derivatives R140Q and C705Y) were produced in HEK
293T cells transiently transfected with pcDNA 3.0 plasmid constructs and purified
as previously described40. The following PAGE-purified oligonucleotides, used for
the DNA substrate preparation, were purchased from Sigma: fluorescently-labeled
D1 oligonucleotide (5′-[6FAM]CTACTACCCCCACCCTCACAACCTTTTTTTTT
TTTTT-3′); D3 (5′- TTTTTTTTTTTTTTGGTTGTGAGGGTGGGGGTAGTAG-
3′) and Cap1 (5′- CTACTACCCCCACCCTCACAACC-3′). For preparation of the
forked DNA substrate, the D1 oligonucleotide was annealed to a 3-fold molar
excess of the D3 oligonucleotide by incubation at 95 °C for 5 min and gradually
cooled below 30 °C. DNA helicase assays were carried out in reaction mixtures
(20 μL) containing the indicated proteins in buffer 25 mM Hepes-NaOH pH 7.2,
1 mM MgCl2, 25 mM K-acetate, 1 mM dithiothreitol, 0.1 mg/mL BSA, 1 mM ATP,
10 nM DNA substrate (D1:D3 annealed oligonucleotides) and 100 nM Cap1.
Assays were initiated by addition of the indicated proteins and then incubated for
20 min at 37 °C. Reactions were quenched with the addition of 5 μl of 5 x stop
solution (0.5% [w:v] SDS, 40 mM EDTA, 0.5 mg/ ml proteinase K, 20% [v:v]
glycerol). Samples were run on a 8% polyacrylamide-bis (29:1) gel in TBE con-
taining 0.1% (w:v) SDS at a constant voltage of 100 V. After the electrophoresis,
gels were analyzed using an imaging system (VersaDoc, BioRad Laboratories)
instrument. Displaced oligonucleotide was quantified using the ImageJ program
(version 1.52) and any free oligonucleotide in the absence of protein was sub-
tracted. The enzymatic assays were carried out in triplicate.
Generation of DDX11-G57R mice. A 25 residue single-stranded DNA oligonu-
cleotide was designed to substitute a single nucleotide in the endogenous DDX11
gene in mouse embryonic stem (ES) cells to exchange glycine codon 57 for an
arginine codon. Oligonucleotide-directed gene modification was performed
essentially as described87. Mutant mice were generated by injecting mutant ES cells
into C57Bl/6 blastocysts following standard procedures. All animal study protocols
were approved by the NKI Animal Welfare Body. Mutant and wild-type DDX11
alleles were distinguished using mutant- and wild-type-specific PCR primers.
Primer sequences are listed in Supplementary Table 1.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
DDX11 sequencing reads from WABS patients have been deposited to the Sequence
Reads Archive (SRA) with accession code PRJNA645773. For sequence alignments, we
used Homo sapiens chromosome 12, GRCh38.p13 Primary Assembly (accession
NC_000012.12, which contains both DDX11 and DDX12p gene sequences); as well as
DDX11 transcript, accession NM_030653.4, and DDX12p transcript, accession
NR_033399.1. The here obtained sequence of the DDX12p transcript of RPE1-TERT
cells has been deposited to GenBank, and is available with accession code MT747418. All
other relevant data supporting the key findings of this study are available within the
article and its Supplementary Information files, the source data, or from the
corresponding authors upon reasonable request. Source data are provided with
this paper.
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